<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Aclarion Inc — News on 6ix</title>
<link>https://6ix.com/company/aclarion-inc</link>
<description>Latest news and press releases for Aclarion Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 28 Apr 2026 10:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/aclarion-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835422a78dffbe2df0e12aa.webp</url>
<title>Aclarion Inc</title>
<link>https://6ix.com/company/aclarion-inc</link>
</image>
<item>
<title>Aclarion Appoints Daniel Keefe as Commercial Director, Western U.S., to Drive Continued Adoption of Nociscan</title>
<link>https://6ix.com/company/aclarion-inc/news/aclarion-appoints-daniel-keefe-as-commercial-director-western-us-to-drive-continued-adoption-of-nociscan</link>
<guid isPermaLink="true">https://6ix.com/company/aclarion-inc/news/aclarion-appoints-daniel-keefe-as-commercial-director-western-us-to-drive-continued-adoption-of-nociscan</guid>
<pubDate>Tue, 28 Apr 2026 10:00:00 GMT</pubDate>
<description>Commercial leader with proven track record of driving growth, surgeon adoption, and market expansion with innovative spine and surgical technologiesExpansion of commercial team reflects increasing demand for Nociscan, supported by triple-digit growth in utilization BROOMFIELD, Colo., April 28, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algori</description>
</item>
<item>
<title>Aclarion Announces $2.5 Million Stock Repurchase Plan</title>
<link>https://6ix.com/company/aclarion-inc/news/aclarion-announces-dollar25-million-stock-repurchase-plan-12</link>
<guid isPermaLink="true">https://6ix.com/company/aclarion-inc/news/aclarion-announces-dollar25-million-stock-repurchase-plan-12</guid>
<pubDate>Wed, 22 Apr 2026 04:00:00 GMT</pubDate>
<description>Highlights Disciplined Capital Allocation While Supporting Continued Nociscan® Adoption BROOMFIELD, Colo., April 22, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc.,</description>
</item>
<item>
<title>Aclarion Secures U.S. Patent Advancing Scalable, AI-Driven Assessment of Chronic Low Back Pain</title>
<link>https://6ix.com/company/aclarion-inc/news/aclarion-secures-us-patent-advancing-scalable-ai-driven-assessment-of-chronic-low-back-pain</link>
<guid isPermaLink="true">https://6ix.com/company/aclarion-inc/news/aclarion-secures-us-patent-advancing-scalable-ai-driven-assessment-of-chronic-low-back-pain</guid>
<pubDate>Thu, 16 Apr 2026 04:00:00 GMT</pubDate>
<description>Patent covers use of AI in workflows of future products to accelerate company’s ability to scale and enhance already strong gross marginsExpands intellectual</description>
</item>
<item>
<title>Aclarion Receives Pinnacle Award for AI Innovation</title>
<link>https://6ix.com/company/aclarion-inc/news/aclarion-receives-pinnacle-award-for-ai-innovation</link>
<guid isPermaLink="true">https://6ix.com/company/aclarion-inc/news/aclarion-receives-pinnacle-award-for-ai-innovation</guid>
<pubDate>Tue, 14 Apr 2026 04:00:00 GMT</pubDate>
<description>Recognition Follows 2025 HLTH Digital Health Award for Nociscan Award Winning AI Targets a Large and Costly Chronic Low Back Pain Market BROOMFIELD, Colo.,</description>
</item>
<item>
<title>Aclarion Announces Agreement with Weill Cornell Medicine</title>
<link>https://6ix.com/company/aclarion-inc/news/aclarion-announces-agreement-with-weill-cornell-medicine</link>
<guid isPermaLink="true">https://6ix.com/company/aclarion-inc/news/aclarion-announces-agreement-with-weill-cornell-medicine</guid>
<pubDate>Wed, 08 Apr 2026 04:00:00 GMT</pubDate>
<description>Expands use of Nociscan in groundbreaking trial BROOMFIELD, Colo., April 08, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq:</description>
</item>
<item>
<title>Aclarion Highlights Growing Adoption of Nociscan at The London Clinic with New Physician Video</title>
<link>https://6ix.com/company/aclarion-inc/news/aclarion-highlights-growing-adoption-of-nociscan-at-the-london-clinic-with-new-physician-video</link>
<guid isPermaLink="true">https://6ix.com/company/aclarion-inc/news/aclarion-highlights-growing-adoption-of-nociscan-at-the-london-clinic-with-new-physician-video</guid>
<pubDate>Tue, 07 Apr 2026 04:00:00 GMT</pubDate>
<description>Video featuring Mr. John Sutcliffe, Lead Clinician at The London Spine Clinic, highlights real-world physician experience with Nociscan in clinical</description>
</item>
<item>
<title>Aclarion Publishes CEO Shareholder Letter Highlighting Strategic Progress and 2026 Catalysts</title>
<link>https://6ix.com/company/aclarion-inc/news/aclarion-publishes-ceo-shareholder-letter-highlighting-strategic-progress-and-2026-catalysts</link>
<guid isPermaLink="true">https://6ix.com/company/aclarion-inc/news/aclarion-publishes-ceo-shareholder-letter-highlighting-strategic-progress-and-2026-catalysts</guid>
<pubDate>Thu, 19 Mar 2026 04:00:00 GMT</pubDate>
<description>Pursuing reimbursement coverage from one or more regional insurance providers in the United States as an important step toward broader payer adoption Initial</description>
</item>
<item>
<title>Aclarion, Inc. Adopts Limited Duration Stockholder Rights Plan</title>
<link>https://6ix.com/company/aclarion-inc/news/aclarion-inc-adopts-limited-duration-stockholder-rights-plan</link>
<guid isPermaLink="true">https://6ix.com/company/aclarion-inc/news/aclarion-inc-adopts-limited-duration-stockholder-rights-plan</guid>
<pubDate>Thu, 19 Mar 2026 04:00:00 GMT</pubDate>
<description>BROOMFIELD, Colo., March 19, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc. (Nasdaq: ACON, ACONW) (“Aclarion” or the “Company”) today announced that its Board of</description>
</item>
<item>
<title>Aclarion to Participate in the 38th Annual ROTH Conference, Highlighting Key 2026 Catalysts and Strong Balance Sheet</title>
<link>https://6ix.com/company/aclarion-inc/news/aclarion-to-participate-in-the-38th-annual-roth-conference-highlighting-key-2026-catalysts-and-strong-balance-sheet</link>
<guid isPermaLink="true">https://6ix.com/company/aclarion-inc/news/aclarion-to-participate-in-the-38th-annual-roth-conference-highlighting-key-2026-catalysts-and-strong-balance-sheet</guid>
<pubDate>Tue, 17 Mar 2026 04:00:00 GMT</pubDate>
<description>BROOMFIELD, Colo., March 17, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare</description>
</item>
<item>
<title>Aclarion CEO Brent Ness to Attend LSI USA 2026</title>
<link>https://6ix.com/company/aclarion-inc/news/aclarion-ceo-brent-ness-to-attend-lsi-usa-2026</link>
<guid isPermaLink="true">https://6ix.com/company/aclarion-inc/news/aclarion-ceo-brent-ness-to-attend-lsi-usa-2026</guid>
<pubDate>Thu, 12 Mar 2026 04:00:00 GMT</pubDate>
<description>BROOMFIELD, Colo., March 12, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare</description>
</item>
<item>
<title>Aclarion Publishes 2026 Shareholder Letter from the Chairman</title>
<link>https://6ix.com/company/aclarion-inc/news/aclarion-publishes-2026-shareholder-letter-110000689</link>
<guid isPermaLink="true">https://6ix.com/company/aclarion-inc/news/aclarion-publishes-2026-shareholder-letter-110000689</guid>
<pubDate>Thu, 05 Feb 2026 11:00:00 GMT</pubDate>
<description>Company anticipates no capital raises prior to expected value enhancing catalysts Cash runway into 2028ATM terminated in early 2025 and ELOC expired December 31, 2025 BROOMFIELD, Colo., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today anno</description>
</item>
<item>
<title>Aclarion Adds High-Volume Practice, Source Healthcare, to Support Nociscan Growth and Real-World Evidence Generation</title>
<link>https://6ix.com/company/aclarion-inc/news/aclarion-adds-high-volume-practice-110000429</link>
<guid isPermaLink="true">https://6ix.com/company/aclarion-inc/news/aclarion-adds-high-volume-practice-110000429</guid>
<pubDate>Tue, 03 Feb 2026 11:00:00 GMT</pubDate>
<description>Expands availability of Nociscan in the greater Los Angeles areaReinforces Nociscan’s non-invasive advantage with real-world clinical validation compared to anesthetic discography, a spinal injection procedureSupports scalable growth strategy while building data assets critical to payer and provider adoption BROOMFIELD, Colo., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging</description>
</item>
<item>
<title>Aclarion Strengthens Balance Sheet and Extends Cash Runway Into 2028</title>
<link>https://6ix.com/company/aclarion-inc/news/aclarion-strengthens-balance-sheet-extends-110000498</link>
<guid isPermaLink="true">https://6ix.com/company/aclarion-inc/news/aclarion-strengthens-balance-sheet-extends-110000498</guid>
<pubDate>Tue, 13 Jan 2026 11:00:00 GMT</pubDate>
<description>Debt-Free Balance Sheet With $21.6 Million in CashBROOMFIELD, Colo., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the closing of a $10.4 million common-stock-only financing at $5.18 per share in a clean capital raise structur</description>
</item>
<item>
<title>Aclarion Provides 2025 Update and 2026 Corporate Outlook</title>
<link>https://6ix.com/company/aclarion-inc/news/aclarion-provides-2025-2026-corporate-110000529</link>
<guid isPermaLink="true">https://6ix.com/company/aclarion-inc/news/aclarion-provides-2025-2026-corporate-110000529</guid>
<pubDate>Thu, 08 Jan 2026 11:00:00 GMT</pubDate>
<description>Quarterly Nociscan scan volumes increased 114% year-over-year in Q4 2025Annual Nociscan scan volumes increased 69% year-over-year in 2025Debt-free balance sheet with $12.0 million in cash as of December 31, 2025, extending cash runway into 2027 and providing strategic flexibility for continued commercial growthCompany aims to enroll approximately 25% of patients in CLARITY trial by the end of Q2 2026, with the first internal readout on interim data anticipated in Q3 2026 BROOMFIELD, Colo., Jan.</description>
</item>
<item>
<title>Aclarion Announces First Patient Enrollments at Two Additional CLARITY Trial Sites and Provides Guidance on Expected Availability of Initial Data</title>
<link>https://6ix.com/company/aclarion-inc/news/aclarion-announces-first-patient-enrollments-110000185</link>
<guid isPermaLink="true">https://6ix.com/company/aclarion-inc/news/aclarion-announces-first-patient-enrollments-110000185</guid>
<pubDate>Tue, 06 Jan 2026 11:00:00 GMT</pubDate>
<description>Northwestern and Scripps Health join two previously announced sites in achieving this critical patient enrollment milestone Seven leading U.S. spine centers have now completed the regulatory and operational requirements to screen and enroll patients in CLARITY First readout on interim data expected after initial cohort of patients achieves 3-month follow up visit in 3Q 2026 BROOMFIELD, Colo., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a</description>
</item>
<item>
<title>Aclarion Announces Publication of Nociscan Article in Special Pain Issue of the International Journal of Spine Surgery (IJSS)</title>
<link>https://6ix.com/company/aclarion-inc/news/aclarion-announces-publication-nociscan-article-130000350</link>
<guid isPermaLink="true">https://6ix.com/company/aclarion-inc/news/aclarion-announces-publication-nociscan-article-130000350</guid>
<pubDate>Thu, 04 Dec 2025 13:00:00 GMT</pubDate>
<description>Featured article strengthens growing body of clinical evidence for Nociscan by highlighting a successful case studySpecial Pain issue features breakthrough innovations shaping the future of spine careIJSS publishes over 150 articles annually representing 40+ nations BROOMFIELD, Colo., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algor</description>
</item>
<item>
<title>Aclarion Appoints Jason Brosniak as Commercial Director to Drive Adoption and Market Expansion in the Eastern U.S.</title>
<link>https://6ix.com/company/aclarion-inc/news/aclarion-appoints-jason-brosniak-commercial-130000870</link>
<guid isPermaLink="true">https://6ix.com/company/aclarion-inc/news/aclarion-appoints-jason-brosniak-commercial-130000870</guid>
<pubDate>Tue, 02 Dec 2025 13:00:00 GMT</pubDate>
<description>Proven commercial leader with 20+ years of experience driving revenue growth and market adoption for early-stage and high-growth MedTech companiesStrong track record of launching breakthrough technologies across spine, neurosurgery and pain managementStrengthens Aclarion’s commercial execution as the Company expands adoption and payer engagement across the Eastern U.S. BROOMFIELD, Colo., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a heal</description>
</item>
<item>
<title>Aclarion Appoints Dan Isherwood as UK Commercial Director to Drive Adoption and Market Expansion</title>
<link>https://6ix.com/company/aclarion-inc/news/aclarion-appoints-dan-isherwood-uk-110000065</link>
<guid isPermaLink="true">https://6ix.com/company/aclarion-inc/news/aclarion-appoints-dan-isherwood-uk-110000065</guid>
<pubDate>Wed, 05 Nov 2025 11:00:00 GMT</pubDate>
<description>Marks Aclarion’s first commercial sales hire with seasoned HealthTech leader and proven track record of advancing musculoskeletal imaging and spinal surgeryExperiencing strong commercial traction in UK as first market worldwide with private insurers covering NociscanNociscan reimbursed by three of top four private insurers in UK, giving access to more than 5.2 million covered lives BROOMFIELD, Colo., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, AC</description>
</item>
<item>
<title>Aclarion Wins “Rising Star” at 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH</title>
<link>https://6ix.com/company/aclarion-inc/news/aclarion-wins-rising-star-2025-100000766</link>
<guid isPermaLink="true">https://6ix.com/company/aclarion-inc/news/aclarion-wins-rising-star-2025-100000766</guid>
<pubDate>Wed, 22 Oct 2025 10:00:00 GMT</pubDate>
<description>Company previously announced it was selected as a finalist from more than 1,800 submissions Award win underscores growing impact of Aclarion’s breakthrough Nociscan solution for chronic low back pain BROOMFIELD, Colo., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back</description>
</item>
<item>
<title>Aclarion Provides Corporate Update Highlighting Market Expansion as CLARITY Trial Advances Toward Key Data Catalyst</title>
<link>https://6ix.com/company/aclarion-inc/news/aclarion-provides-corporate-highlighting-market-100900878</link>
<guid isPermaLink="true">https://6ix.com/company/aclarion-inc/news/aclarion-provides-corporate-highlighting-market-100900878</guid>
<pubDate>Tue, 14 Oct 2025 10:09:00 GMT</pubDate>
<description>Debt-free balance sheet with $13.3 million in cash as of today ($15.11 per share fully diluted) providing strategic flexibility for continued commercial growth Nociscan scan volumes increase +89% year-over-year with third consecutive quarter of record utilization across U.S., U.K., and E.U. markets CLARITY pivotal trial progressing on schedule and early 3-month readouts expected Q2 2026 as AI-driven disc pain biomarker validation continues Webcast scheduled for October 20th at 12:00 pm PT at the</description>
</item>
</channel>
</rss>